OncoMatch/Clinical Trials/NCT06363994

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Is NCT06363994 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Orelabrutinib and Bendamustine for mantle cell lymphoma.

Phase 3RecruitingInnoCare Pharma Inc.NCT06363994Data as of May 2026

Treatment: Orelabrutinib · Bendamustine · Rituximab — Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CCND1 overexpression

expression of Cyclin D1

Required: IGH t(11;14) chromosomal translocation

t (11; 14) chromosomal translocation

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify